← Leaderboards
Christopher H Clegg
Tria Bioscience Corporation
$11,822,906
Attributed
$11,822,906
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2009–20$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$11,597,940 · 7
CDC$224,966 · 1
By mechanism
UH3$4,110,456 · 1
R44$3,000,000 · 1
R43$2,513,634 · 5
UH2$2,198,816 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesLeadBaseAdjuvantPreventAntigensAntibody FormationImmunogenicityCessation Of LifeT-LymphocyteNovel VaccinesInnovationProductionSafetyVaccine AdjuvantNonhuman PrimateAntibodiesAnimal ModelSeriesB-LymphocytesPharmaceutical PreparationsCommercializationCyclic GmpMediating
Grant awards (17)
Preclinical development of a TriCoil-based nicotine vaccine$1,364,701
UH3 · FY2020 · DA · contact PI
Preclinical development of a TriCoil-based nicotine vaccine$1,365,834
UH3 · FY2019 · DA · contact PI
Preclinical development of a TriCoil-based nicotine vaccine$1,379,921
UH3 · FY2018 · DA · contact PI
Synthetic Universal Flu Vaccine$224,966
R43 · FY2018 · IP · contact PI
Preclinical development of a TriCoil-based nicotine vaccine$1,024,634
UH2 · FY2016 · DA · contact PI
Preclinical development of a TriCoil-based nicotine vaccine$1,174,182
UH2 · FY2015 · DA · contact PI
Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients$280,636
R43 · FY2014 · AI · contact PI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2013 · AI · contact PI
Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu$300,000
R43 · FY2013 · AI · contact PI
Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients$298,747
R43 · FY2013 · AI · contact PI
Advanced Design of a Nicotine Vaccine for Smoking Cessation$201,390
R43 · FY2013 · DA · contact PI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2012 · AI · contact PI
Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu$300,000
R43 · FY2012 · AI · contact PI
Advanced Design of a Nicotine Vaccine for Smoking Cessation$151,451
R43 · FY2012 · DA · contact PI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2011 · AI · contact PI
Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA$316,224
R43 · FY2010 · AI · contact PI
Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA$440,220
R43 · FY2009 · AI · contact PI